Daisuke Fujisawa1,2, Jennifer S Temel1, Joseph A Greer1, Areej El-Jawahri1, Lara Traeger1, Jamie M Jacobs1, Stacy Cutrono3, William F Pirl1,4. 1. Massachusetts General Hospital, Cancer Center, Boston, MA. 2. Keio University School of Medicine, Department of Neuropsychiatry and Palliative Care Center, Tokyo, Japan. 3. Sylvester Comprehensive Cancer Center, Miami University, Miller School of Medicine, Miami, FL. 4. Dana-Faber Cancer Institute, Psychosocial Oncology and Palliative Care, Boston, MA.
Abstract
OBJECTIVE: Wearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer. METHOD: We collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy - Trial Outcome Index), and survival. RESULT: Actigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy - Trial Outcome Index (r = -0.53, p < 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r = 0.37, p < 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10% increase in this measure, the hazard ratio (HR) was 1.48 (95% confidence interval [CI95%] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI95% = 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80, CI95% = 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI95% = 1.10, 3.42), whereas ECOG PS did not predict survival. SIGNIFICANCE OF RESULTS: Actigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.
OBJECTIVE: Wearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer. METHOD: We collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy - Trial Outcome Index), and survival. RESULT: Actigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy - Trial Outcome Index (r = -0.53, p < 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r = 0.37, p < 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10% increase in this measure, the hazard ratio (HR) was 1.48 (95% confidence interval [CI95%] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI95% = 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80, CI95% = 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI95% = 1.10, 3.42), whereas ECOG PS did not predict survival. SIGNIFICANCE OF RESULTS: Actigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.
Authors: Jasleen Minhas; Haochang Shou; Steven Hershman; Roham Zamanian; Corey E Ventetuolo; Todd M Bull; Anna Hemnes; Murali M Chakinala; Stephen Mathai; Nadine Al-Naamani; Susan Ellenberg; Lea Ann Matura; Steven M Kawut; Anna Shcherbina Journal: Ann Am Thorac Soc Date: 2022-04
Authors: Zaki Hasnain; Tanachat Nilanon; Ming Li; Aaron Mejia; Anand Kolatkar; Luciano Nocera; Cyrus Shahabi; Frankie A Cozzens Philips; Jerry S H Lee; Sean E Hanlon; Poorva Vaidya; Naoto T Ueno; Sriram Yennu; Paul K Newton; Peter Kuhn; Jorge Nieva Journal: JCO Clin Cancer Inform Date: 2020-06
Authors: Shu Ning Ch'ng; Joanne A McVeigh; David Manners; Terry Boyle; Carolyn J Peddle-McIntyre; Rajesh Thomas; Jeanie Leong; Samantha Bowyer; Kirsten Mooney; Leon Straker; Daniel A Galvão; Vinicius Cavalheri Journal: J Clin Med Date: 2022-10-04 Impact factor: 4.964
Authors: Milan Kos; Esther N Pijnappel; Laurien M Buffart; Britt R Balvers; Caroline S Kampshoff; Johanna W Wilmink; Hanneke W M van Laarhoven; Martijn G H van Oijen Journal: Support Care Cancer Date: 2021-06-12 Impact factor: 3.603